Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

The other point which makes this more significant

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
farrell90 Member Profile
Member Level 
Followed By 86
Posts 2,939
Boards Moderated 0
Alias Born 01/28/06
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 2:16:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/21/2020 9:33:35 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2020 9:03:05 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/28/2020 9:30:58 AM
Cannabis and CBD Stocks are Old News, The Next Hot Peripheral Sector is Here! InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2020 2:21:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/1/2020 4:39:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2020 12:00:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/6/2020 12:01:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/27/2020 12:01:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/13/2020 4:06:02 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/13/2020 4:02:49 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 12/26/2019 5:19:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/26/2019 5:16:58 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 12/16/2019 8:32:20 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 9:24:21 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/22/2019 6:01:03 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 10/17/2019 5:24:36 PM
Annual Report (10-k) Edgar (US Regulatory) - 9/30/2019 4:38:42 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/20/2019 4:36:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 4:34:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:52:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:51:57 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/13/2019 4:11:11 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 8/2/2019 4:29:30 PM
farrell90 Member Level  Saturday, 07/13/19 01:38:49 PM
Re: williamssc post# 267347
Post # of 299747 
The other point which makes this more significant is OraLogiK has signed very few agreements for use of their technology. The May 2018 agreement with Novartis for its product was its first licensing agreement.

https://www.prnewswire.com/news-releases/bdd-pharma-secures-license-agreement-with-top-pharma-company-for-timed-release-oralogik-technology-684044281.html


BDD, the developer of OraLogiK, is based in Scotland. Relatively close to IPIX's European subsidiary's office

https://www.bddpharma.com/about

Plus IPIX had another agreement with CoreRx to develop Brilacidin packets for Oral Mucositis.

https://markets.businessinsider.com/news/stocks/innovation-pharmaceuticals-signs-drug-product-manufacturing-contract-with-corerx-to-formulate-and-package-brilacidin-for-oral-mucositis-in-sachet-form-1027373481

CoreRX, an American company based in Floida, also develops oral segmental release pills with its multilayered technology.

https://www.corerxpharma.com/services/formulation-development/

"Dr. Arthur P. Bertolino, M.D. Ph.D. is President, Chief Medical Officer, Director of the Company. Dr. Bertolino held several key positions at Novartis Institutes for Biomedical Research (“NIBR”) from 2008 to 2013, including Vice President of Dermatology and Vice President & Global Head of Translational Medicine for Dermatology. During his time at NIBR, Dr. Bertolino was integral to the marketing approval of Ilaris (canakinumab) in the United States, European Union and Switzerland. He also led the early clinical program of Cosentyx™ (secukinumab) and late stage supportive submission studies."

https://www.reuters.com/finance/stocks/company-officers/IPIX.PK

When you add Dr Bertilino's past connection to Novartis there is a lot of circumstantial evidence to suspect Novartis as one of IPIX suitors.

GLTA Farrell





Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist